newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

  • Cogent Biosciences announced multiple upcoming posters highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients at the 2026 AAAAI Annual Meeting in Philadelphia.
  • The meeting is scheduled for February 27-March 2, 2026, with seven poster presentations taking place on February 28, 2026, in Hall A of the Convention Center.
  • In December 2025, the company submitted a New Drug Application for bezuclastinib in NonAdvSM to the FDA based on positive data from the SUMMIT pivotal trial.
  • The FDA submission follows Breakthrough Therapy Designation for bezuclastinib in patients with SSM and NonAdvSM who have received prior avapritinib.
  • Poster topics include expanded trial results, bone formation marker changes, patient experience, symptom burden improvement, correlation between symptom improvement and objective disease measures, and results in subgroups with unmet need.
  • Bezuclastinib is a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation and other KIT exon 17 mutations associated with systemic mastocytosis.
  • The company also has an ongoing Phase 1 study of an FGFR2/3 inhibitor and is developing targeted therapies for mutations in ErbB2, PI3Kα, KRAS, and JAK2.
  • Cogent Biosciences is headquartered in Waltham, MA, and Boulder, CO.